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Accepted 25 March 2013Cesarean scar pregnancy (CSP) is a rare form of ectopic preg-
nancy, but its incidence is substantially increasing owing to
increasing cesarean section rates worldwide [1,2]. CSP may present
from 5 weeks to 16 weeks of gestational age. It is a dangerous
condition that can be life-threatening because of the potential for
profuse massive bleeding, uterine rupture, and hemodynamic
instability [3]. Here, we describe a surgical procedure for refractory
CSP that prevents massive blood loss and conserves the uterus to
maintain further fertility, quality of life, and female health.
A 42-year-old married, Taiwanese, G2P2 female presented with
an overdue menstrual cycle and persistent lower abdominal pain
for more than 1 week. Her previous history revealed a lower
segmental transverse cesarean section. A transvaginal ultrasound
revealed an embryonic gestational mass in the anterior lower
uterine cavity that was compatible with a CSP at 6 gestational
weeks (Fig. 1) and the level of serum b-human chorionic gonado-
tropin (b-hCG) was 6050 mIU/mL. Three days later, the serum b-
hCG increased to 12,786 mIU/mL. The CSP was terminated by an
intramuscular injection of methotrexate (50 mg/m2) initially to
maintain fecundity. Unfortunately, on the 9th day after the initial
methotrexate administration, the serum b-hCG increased to
43,026 mIU/mL (Fig. 2) and the transabdominal ultrasound
revealed that the CSP was consistent with a 9-week gestational
period (crown-rump length: 23 mm, Fig. 3). Surgical intervention
was indicated because of worsening symptoms. Cytotec (miso-
prostol) was given vaginally at a dose of 200mg for cervical priming
1 hour prior to surgery. The bulging cervix was dilated using a
Hegar dilator. A placental forceps was introduced into the uterus
and used to carefully remove the gestational tissue, as is performedConﬂicts of interest: The authors have no conﬂicts of interest to declare.
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the implanted site with 50 mL of normal saline. This device pro-
vided a tamponade effect to achieve hemostasis. There was little
vaginal bleeding, similar to the amount associated with menstru-
ation. We removed the Foley catheter 24 hours later. The serum
levels of b-hCG declined to 450 mIU/mL progressively after surgery.
The majority of CSPs are diagnosed based on a patient’s history,
clinical manifestations, serum b-hCG titer, and transvaginal so-
nography. The following ultrasound criteria have been suggested
for the diagnosis of CSP [3], including an empty uterine cavity,
without contact with the sac; a clearly visible empty cervical canal,
without contact with the sac; the presence of a gestation sac with
or without a fetal pole and with or without fetal cardiac activity in
the anterior part of the uterine isthmus; and the absence of or a
defect in the myometrial tissue between the bladder and the sac.
The conservative management of CSP is an appropriate option
when there is a high suspicion that the trophoblast has reached the
vesicouterine space on the bladder wall. The medical treatment
includes systemic methotrexate injection, local embryocides, or
combination therapy. Signiﬁcant differences between patients who
receive conservative therapy and patients who receive additional
uterine curettage have been found regarding the success rate (76.2%
vs. 90.0%, respectively) and hysterectomy rate (19.0% vs. 8.0%,
respectively) [2]. However, there is still a risk of rupture of the CSP
with massive bleeding after medical treatment. The surgical in-
terventions for CSP include hysteroscopy, laparoscopy, uterine
curettage and sac aspiration, uterine artery embolization, and even
hysterectomy if other treatment modalities have failed. Some pa-
tients with CSP have been successfully treated using suction
curettage, but this technique may fail and cause complications [1].
Methotrexate is a folic acid antagonist that interferes with DNA
synthesis and has been used more successfully if the level of serum
b-hCG is <15,000 mIU/mL [4]. Other antineoplastic agents such as
etoposide and actinomycin-D have been reported for second-line
chemotherapy [4,5], but the side effects of etoposide including
myelosuppression, which usually manifests as reversible leuko-
penia, total alopecia, and gastrointestinal toxicity have been re-
ported [5]. In this case, the patient’s serum b-hCG level increased
despite methotrexate administration, and surgical intervention as
the standard is considered. To avoid massive uterine bleeding and
destruction of the uterine structure, we used cytotec (misoprostol)by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. A midline transvaginal image demonstrating a gestational sac in the anterior
part of the uterine isthmus and an empty uterine cavity.
Fig. 2. Serum b-hCG levels and clinical course of the CSP. Arrow indicates the time
point of the methotrexate 50 mg intramuscular injection (D6). Arrowhead indicates
uterine curettage and sac aspiration (D19). b-hCG ¼ b-human chorionic gonadotropin;
CSP ¼ cesarean scar pregnancy.
Fig. 3. A 9-week fetus (arrow) of gestational age (crown-rump length: 23 mm)
implanted in the previous cesarean scar.
Fig. 4. The placental tissue (arrow) and a fetus (arrowhead) were removed carefully.
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lines, misoprostol is recommended prior to hysteroscopy, dilatation
and curettage, surgical abortion, and intrauterine device insertion.
Cervical priming with misoprostol was found to be helpful in
multiparous pregnant females undergoing a surgical abortion
beyond 12 weeks of gestation [6]. Misoprostol, 400 mg, given
vaginally for medical abortion is probably the optimal regimen.
However, it is recommended that thosewith a scarred uterus should
receive lower doses and a double dose should not be given if there is
no initial response [7]. Therefore, we adjusted the dosage to 200mg
vaginally. Uterine cramping pain was found to be a frequent side
effect, and usually responds to nonsteroidal anti-inﬂammatory drug
administration if no contraindication is present [6].
To prevent post-abortion hemorrhage, the compression
methods with rolling gauze and balloon tamponade to compress
the bleeding site were used [8], including the SengstakeneBlake-
more tube, Bakri balloon, Rusch balloon, condom catheters, and
Foley catheters [9]. In this case, we choose the Foley catheter
because of its availability and minimal requirement for its use. The
Foley catheter with a distended balloon have been reported to be
introduced, respectively, into the uterine cavity in postpartum
hemorrhage following unsuccessful use of medicine and uterine
curettage [9]. Therefore, an intrauterine tamponade balloon is one
of the choices in the management of severe hemorrhage and can
prevent more invasive destructive procedures.
CSP is a rare type of ectopic embryo implantation that consti-
tutes a life-threatening condition because of its potentially fatal
complications. The main objectives in the clinical management of
CSP should be to prevent uterine rupture and massive blood loss
and tomaintain fertility. The use of misoprostol for cervical priming
facilitated the transcervical procedures. Furthermore, the ﬁnal
pathological examinations have revealed the presence of a cluster
of trophoblast cells and absence of uterine myometrial muscle
bundles. The presented case demonstrates the successful treatment
of CSP using misoprostol for cervical priming and a balloon to
achieve post-operation hemostasis.References
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